Long-Term Therapeutic Efficacy of Intravenous AAV-Mediated Hamartin Replacement in Mouse Model of Tuberous Sclerosis Type 1.
- DOI
- 10.1016/j.omtm.2019.08.003
- Published
- 2019 Dec 13
- Container
- Molecular therapy. Methods & clinical development
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.omtm.2019.08.003,
title = {Long-Term Therapeutic Efficacy of Intravenous AAV-Mediated Hamartin Replacement in Mouse Model of Tuberous Sclerosis Type 1.},
author = {Prabhakar S and Cheah PS and Zhang X and Zinter M and Gianatasio M and Hudry E and Bronson RT and Kwiatkowski DJ and Stemmer-Rachamimov A and Maguire CA and Sena-Esteves M and Tannous BA and Breakefield XO},
year = {2019},
journal = {Molecular therapy. Methods \& clinical development},
doi = {10.1016/j.omtm.2019.08.003},
url = {https://doi.org/10.1016/j.omtm.2019.08.003}
}RIS
TY - JOUR TI - Long-Term Therapeutic Efficacy of Intravenous AAV-Mediated Hamartin Replacement in Mouse Model of Tuberous Sclerosis Type 1. AU - Prabhakar S AU - Cheah PS AU - Zhang X AU - Zinter M AU - Gianatasio M AU - Hudry E AU - Bronson RT AU - Kwiatkowski DJ AU - Stemmer-Rachamimov A AU - Maguire CA AU - Sena-Esteves M AU - Tannous BA AU - Breakefield XO PY - 2019 JO - Molecular therapy. Methods & clinical development DO - 10.1016/j.omtm.2019.08.003 UR - https://doi.org/10.1016/j.omtm.2019.08.003 ER -
APA
S, P., PS, C., X, Z., M, Z., M, G., E, H., RT, B., DJ, K., A, S., CA, M., M, S., BA, T., & XO, B. (2019). Long-Term Therapeutic Efficacy of Intravenous AAV-Mediated Hamartin Replacement in Mouse Model of Tuberous Sclerosis Type 1.. Molecular therapy. Methods & clinical development. https://doi.org/10.1016/j.omtm.2019.08.003
Source records
- pubmed · retrieved 2026-09-25T17:17:18.467Z